<p>A) Animals with PC-3 subcutaneous tumor xenografts were treated with the <i>dl</i>1102 (filled triangle) or <i>dl</i>1104 (filled circle) mutants or mock treated with <i>dl</i>312 (filled square) at 1×10<sup>9</sup> vp (i.t. injections on day 1, 3, and 5) with and without docetaxel at 10 mg/kg (D10; i.p. administration on day 2 and 8, open squares), and tumor growth was monitored. *p<0.05, treatments compared with mock and single-agent treatments (one-way ANOVA), p<0.05 for <i>dl</i>1102 alone compared to mock, n = 6. B). In a second study animals with PC-3 subcutaneous tumor xenografts were treated as above with the indicated suboptimal doses of mutants at 1×10<sup>9</sup> vp and docetaxel at 10 mg/kg (D10) or the respective combination...
<p><b>A</b>) Mice bearing PC3-luc tumors were treated with 10 mg/kg docetaxel (CTx) or their tumors ...
<p><b>a</b>, Mice bearing BT483-derived breast cancer xenografts with average tumor size of ∼75 mm<s...
<p>Due to the failure of many drugs in the transition from the preclinical setting into clinical tri...
<p>(<b>A</b>) MYC-CaP/CR cells (5×10<sup>6</sup>), (<b>B</b>) LuCaP23.1 AI tumor chunk (∼5 mm<sup>2<...
<p>Tumor growth curves for PC-3M-luc, PC-3M-luc-scr, PC-3M-luc -CD44-KD and PC-3M-luc-CD147-KD xenog...
<p>Female mice were transplanted in one mammary fat pad with chemoresistant breast cancer xenograft ...
<p>(<b>A</b>). U-2932 xenograft mice (n = 12 per cohort) were treated with saline (control), M = 30 ...
<p>NCR nu/nu homozygous male mice were subcutaneously implanted with (A) H1993, (B) A549, (C) H292 a...
<p>Xenografts-bearing mice were randomly assigned into four therapeutic groups (6–14 mice per group)...
<p>A-D) PPC1 cells were infected with 25 MOI Ad-GFP or Ad-AC and either 25 MOI Ad-GFP, Ad-WT-PTEN, o...
<p>(A) Groups of female BALB/c mice (n = 20) were inoculated orthotopically with 1×10<sup>5</sup> 4T...
<p>A-D. Effects of combinatorial therapy on DU145 (A), MDA-MB-231 (B), HepG2(C) and RKO (D) xenograf...
<p>(A) Balb-c nude mice with xenografts derived PC3 cells were treated by oral administration of VK3...
<p>Comparison of average tumor volume (A) and tumor growth rate (B) of MCF-7 Tet-Off/ACSL4 tumor xen...
<p>A, the growth curves of subcutaneous xenografts of BaF3-T674I cells are shown. Nude mice bearing ...
<p><b>A</b>) Mice bearing PC3-luc tumors were treated with 10 mg/kg docetaxel (CTx) or their tumors ...
<p><b>a</b>, Mice bearing BT483-derived breast cancer xenografts with average tumor size of ∼75 mm<s...
<p>Due to the failure of many drugs in the transition from the preclinical setting into clinical tri...
<p>(<b>A</b>) MYC-CaP/CR cells (5×10<sup>6</sup>), (<b>B</b>) LuCaP23.1 AI tumor chunk (∼5 mm<sup>2<...
<p>Tumor growth curves for PC-3M-luc, PC-3M-luc-scr, PC-3M-luc -CD44-KD and PC-3M-luc-CD147-KD xenog...
<p>Female mice were transplanted in one mammary fat pad with chemoresistant breast cancer xenograft ...
<p>(<b>A</b>). U-2932 xenograft mice (n = 12 per cohort) were treated with saline (control), M = 30 ...
<p>NCR nu/nu homozygous male mice were subcutaneously implanted with (A) H1993, (B) A549, (C) H292 a...
<p>Xenografts-bearing mice were randomly assigned into four therapeutic groups (6–14 mice per group)...
<p>A-D) PPC1 cells were infected with 25 MOI Ad-GFP or Ad-AC and either 25 MOI Ad-GFP, Ad-WT-PTEN, o...
<p>(A) Groups of female BALB/c mice (n = 20) were inoculated orthotopically with 1×10<sup>5</sup> 4T...
<p>A-D. Effects of combinatorial therapy on DU145 (A), MDA-MB-231 (B), HepG2(C) and RKO (D) xenograf...
<p>(A) Balb-c nude mice with xenografts derived PC3 cells were treated by oral administration of VK3...
<p>Comparison of average tumor volume (A) and tumor growth rate (B) of MCF-7 Tet-Off/ACSL4 tumor xen...
<p>A, the growth curves of subcutaneous xenografts of BaF3-T674I cells are shown. Nude mice bearing ...
<p><b>A</b>) Mice bearing PC3-luc tumors were treated with 10 mg/kg docetaxel (CTx) or their tumors ...
<p><b>a</b>, Mice bearing BT483-derived breast cancer xenografts with average tumor size of ∼75 mm<s...
<p>Due to the failure of many drugs in the transition from the preclinical setting into clinical tri...